<DOC>
	<DOCNO>NCT00531934</DOCNO>
	<brief_summary>This 2 arm study evaluate management Tarceva-induced skin rash patient non-small cell lung cancer fail first-line chemotherapy advance disease . Eligible patient randomize receive ) doxycycline 100mg po daily b ) preventative treatment ; patient receive Tarceva 150mg/kg po daily . The anticipated time study treatment disease progression intolerable toxicity , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Management Tarceva - Induced Rash Patients With Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , 1875 year age ; confirm nonsmall cell lung cancer ; failure first line chemotherapy advance disease , schedule second line therapy Tarceva . rash etiology study entry ; history significant heart disease ; malignancy ( adequately treat squamous cell skin cancer , situ cancer cervix ) ; history allergic reaction tetracycline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>